TNFRSF17 and Miyoshi myopathy: Taken together, we identified a naturally presented myeloma-associated, BCMA-derived peptide, which constitutes a promising and highly immunogenic target for tailored T-cell-based immunotherapy and monitoring of immunotherapeutic approaches in MM and other B-cell malignancies.